MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · see citing works

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · see citing works

Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents

Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256 · see citing works

Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents

Beranek, D. T. (1990) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(90)90173-2 · Cited by 904 · see citing works

MGMT: its role in cancer aetiology and cancer therapeutics

Gerson, S. L. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1319 · Cited by 817 · see citing works

Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide

Hegi, M. E., Diserens, A., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 782 · see citing works

What's going on 放射線 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005; 352: 987-96. PMID: 15758009.--神経膠腫に対する治療として、放射線治療とテモゾロマイドの併用が世界的な標準的治療となりうることを示唆する論文

荒木, 則. (2006) · Mebio oncology · Cited by 771 · see citing works

MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

Kaina, B., Christmann, M., Naumann, S. C., & Roos, W. P. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 662 · see citing works

Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase

Pegg, A. E., Dolan, M. E., & Moschel, R. C. (1995) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60879-x · Cited by 517 · see citing works

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

Roos, W. P., Batista, L. F. Z., Naumann, S. C., Wick, W., Weller, M., Menck, C. F. M., & Kaina, B. (2006) · Oncogene · doi:10.1038/sj.onc.1209785 · Cited by 499 · see citing works

Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment

Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A., Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2149 · Cited by 450 · see citing works

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M. H., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423 · see citing works

O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

Hermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W. P., Kaina, B., & Weller, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03583.x · Cited by 309 · see citing works

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297 · see citing works

Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

Quinn, J. A., Desjardins, A., WEINGART, J. D., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J. J., Rich, J. N., Friedman, A. H., Reardon, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.502 · Cited by 288 · see citing works

Expression of p53 and Prognosis in Children with Malignant Gliomas

Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J. A., Holmes, E. J., Hamilton, R. L., Yates, A. J., Boyett, J. M., Finlay, J. L., & Sposto, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012224 · Cited by 278 · see citing works

CpG Island Hypermethylation of the DNA Repair Enzyme Methyltransferase Predicts Response to Temozolomide in Primary Gliomas

Paz, M. F., Yayá, R., Rojas-Marcos, I., Reynés, G., Pollán, M., Aguirre‐Cruz, L., García-Lopez, J. L., Piquer, J., Safont, M. J., Balañá, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0392 · Cited by 260 · see citing works

Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.

Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J. T., Alas, L., Li, B., Citron, M. L., Wasserman, P., White, A., et al. (1996) · PubMed · Cited by 244 · see citing works

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

Brandes, A. A., Tosoni, A., Cavallo, G., Bertorelle, R., Gioia, V., Franceschi, E., Biscuola, M., Blatt, V., Crinò, L., & Ermani, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603376 · Cited by 226 · see citing works

Human papillomavirus genotype as a predictor of persistence and development of high‐grade lesions in women with minor cervical abnormalities

Londesborough, P., Ho, L., Terry, G., Cuzick, J. M., Wheeler, C. M., & Singer, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961021)69:5 · Cited by 224 · see citing works

Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex−, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models

Kaina, B., Ziouta, A., Ochs, K., & Coquerelle, T. M. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00187-5 · Cited by 197 · see citing works

O6‐alkylguanine‐DNA alkyltransferase: Role in carcinogenesis and chemotherapy

Margison, G. P., & Santibanez‐Koref, M. (2002) · BioEssays · doi:10.1002/bies.10063 · Cited by 188 · see citing works

Variability and regulation of O6-alkylguanine-DNA alkyltransferase

Margison, G. P. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg005 · Cited by 182 · see citing works

O6-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 Cohort

Pollack, I. F., Hamilton, R. L., Sobol, R. W., Burnham, J. A., Yates, A. J., Holmes, E. J., Zhou, T., & Finlay, J. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.7265 · Cited by 173 · see citing works

Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03

Herrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9104 · Cited by 166 · see citing works

One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma

Wick, W., Steinbach, J. P., Küker, W., DICHGANS, J., BAMBERG, M., & Weller, M. (2004) · Neurology · doi:10.1212/01.wnl.0000127617.89363.84 · Cited by 154 · see citing works

O6-alkylguanine DNA lesions trigger apoptosis

Meikrantz, W. (1998) · Carcinogenesis · doi:10.1093/carcin/19.2.369 · Cited by 147 · see citing works

Inducibility of the DNA Repair Gene Encoding O6-Methylguanine- DNA Methyltransferase in Mammalian Cells by DNA-Damaging Treatments

Fritz, G., Tano, K., MITRA, S. P., & Kaina, B. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.9.4660-4668.1991 · Cited by 145 · see citing works

p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents

Grombacher, T., Eichhorn, U., & Kaina, B. (1998) · Oncogene · doi:10.1038/sj.onc.1202000 · Cited by 141 · see citing works

Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant Glioma

The Neuro-Oncology Working Group of the German Cancer Society (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.509 · Cited by 140 · see citing works

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.

Silber, J. R., Blank, A., Bobola, M. S., Ghatan, S., Kolstoe, D. D., & Berger, M. S. (1999) · PubMed · Cited by 135 · see citing works

Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes

Grombacher, T., MITRA, S. P., & Kaina, B. (1996) · Carcinogenesis · doi:10.1093/carcin/17.11.2329 · Cited by 119 · see citing works

DNA repair in resistance to alkylating anticancer drugs

Kaina, B., & Christmann, M. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40354 · Cited by 117 · see citing works

O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary.

Citron, M. L., Decker, R., Chen, S., Schneider, S., Graver, M. L., Kleynerman, L., Kahn, L. B., White, A., Schoenhaus, M., & Yarosh, D. B. (1991) · PubMed · Cited by 112 · see citing works

Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating xpc, ddb2, and DNA Double-Strand Breaks

Batista, L. F. Z., Roos, W. P., Christmann, M., Menck, C. F. M., & Kaina, B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2964 · Cited by 104 · see citing works

A simplified assay for O6-methylguanine-DNA methyltransferase activity and its application to human neoplastic and non-neoplastic tissues

Myrnes, B., Norstrand, K., Giercksky, K.-E., Sjunneskog, C., & Krokan, H. E. (1984) · Carcinogenesis · doi:10.1093/carcin/5.8.1061 · Cited by 104 · see citing works

Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene.

Harris, L. C., Remack, J. S., Houghton, P. J., & Brent, T. P. (1996) · PubMed · Cited by 95 · see citing works

Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling.

Boldogh, I. R., Ramana, C. V., Chen, Z., Biswas, T., Hazra, T. K., Grösch, S., Grombacher, T., MITRA, S. P., & Kaina, B. (1998) · PubMed · Cited by 92 · see citing works

Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma

Maxwell, J. A., Johnson, S. P., Quinn, J. A., McLendon, R. E., Ali‐Osman, F., Friedman, A. H., Herndon, J. E., Bierau, K., Bigley, J. W., Bigner, D. D., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0106 · Cited by 88 · see citing works

O6‐methylguanine‐DNA methyltransferase activity in breast and brain tumors

Preuss, I., Eberhagen, I., Haas, S. A., Eibl, R. H., Kaufmann, M., Minckwitz, G. V., & Kaina, B. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910610308 · Cited by 88 · see citing works

Induction of murine O6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent.

Rafferty, J. A., Clarke, A. R., Sellappan, D., Santibanez‐Koref, M., Frayling, I. M., & Margison, G. P. (1996) · PubMed · Cited by 82 · see citing works

Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors

Park, T., Riethdorf, S., Riethdorf, L., L�ning, T., & J�nicke, F. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990820)84:4 · Cited by 56 · see citing works

Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue.

Preuss, I., Haas, S. A., Eichhorn, U., Eberhagen, I., Kaufmann, M., Beck, T., Eibl, R. H., Dall, P., Bauknecht, T., Hengstler, J. G., et al. (1996) · PubMed · Cited by 54 · see citing works

Induction of the DNA repair gene O6-methylguanine—DNA methyltransferase by dexamethasone in glioblastomas

Ueda, S., Mineta, T., Nakahara, Y., Okamoto, H., Shiraishi, T., & Tabuchi, K. (2004) · Journal of neurosurgery · doi:10.3171/jns.2004.101.4.0659 · Cited by 47 · see citing works

Local intracerebral administration of O6-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma

Koch, D., Hundsberger, T., Boor, S., & Kaina, B. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9244-8 · Cited by 46 · see citing works

Constitutive expression and inducibility of O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in rat liver cells exhibiting different status of differentiation

Grombacher, T., & Kaina, B. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(94)00073-y · Cited by 37 · see citing works

Stress factors affecting expression of O6-methylguanine-DNA methyltransferase mRNA in rat hepatoma cells

Fritz, G., & Kaina, B. (1992) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(92)90137-o · Cited by 34 · see citing works

p53 Alterations in Colon Tumors

Curtin, K. P., Slattery, M. L., Holubkov, R., Edwards, S. L., Holden, J. A., & Samowitz, W. S. (2004) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200412000-00017 · Cited by 29 · see citing works

Influence of O6‐methylguanine‐DNA methyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumors

Mineura, K., Izumi, I., Watanabe, K., & Kowada, M. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550115 · Cited by 28 · see citing works

Apoptosis and proliferation: correlation with p53 in astrocytic tumours

Sarkar, C., Karak, A. K., Nath, N., Sharma, M. C., Mahapatra, A. K., Chattopadhyay, P., & Sinha, S. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-3015-1 · Cited by 21 · see citing works

Untitled work

Hsing (1996) · doi:10.1002/(sici)1097-0215(19960208)65:4 · Cited by 1 · see citing works

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 779 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

MGMT Status as a Clinical Biomarker in Glioblastoma

Butler, M. K., Pongor, L. S., Su, Y., Xi, L., Raffeld, M. A., Quezado, M., Trepel, J. B., Aldape, K., Pommier, Y. G., & Wu, J. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.010 · Cited by 348 · see citing works

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

Dunn, J. R., Baborie, A., Alam, F., Joyce, K. A., Moxham, M., Sibson, R., Crooks, D. A., Husband, D. J., Shenoy, A., Brodbelt, A. R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605127 · Cited by 322 · see citing works

O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy

Yu, W., Zhang, L., Wei, Q., & Shao, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01547 · Cited by 274 · see citing works

Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation

Christmann, M., & Kaina, B. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt635 · Cited by 245 · see citing works

O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry

Christmann, M., Verbeek, B., Roos, W. P., & Kaina, B. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.06.002 · Cited by 242 · see citing works

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients

Felsberg, J., Rapp, M., Loeser, S., Fimmers, R., Stummer, W., Goeppert, M., Steiger, H.-J., Friedensdorf, B., Reifenberger, G., & Sabel, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2801 · Cited by 202 · see citing works

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts

Kitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., Decker, P. A., Wu, W., Lomberk, G. A., Gupta, S. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0560 · Cited by 151 · see citing works

Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy

Kaina, B., Margison, G. P., & Christmann, M. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0491-7 · Cited by 150 · see citing works

DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas

Kaina, B., & Christmann, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.04.007 · Cited by 141 · see citing works

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

Christmann, M., Nagel, G., Horn, S., Krahn, U., Wiewrodt, D., Sommer, C., & Kaina, B. (2010) · International Journal of Cancer · doi:10.1002/ijc.25229 · Cited by 117 · see citing works

Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome

Lalezari, S., Chou, A. P., Tran, A. N., Solis, O. E., Khanlou, N., Chen, W., Li, S., Carrillo, J., Chowdhury, R., Selfridge, J. M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos308 · Cited by 116 · see citing works

O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems

Silber, J. R., Bobola, M. S., Blank, A., & Chamberlain, M. C. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.004 · Cited by 115 · see citing works

Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications

Zhang, J., Stevens, M. F. G., Laughton, C. A., Madhusudan, S., & Bradshaw, T. D. (2010) · Oncology · doi:10.1159/000306139 · Cited by 110 · see citing works

FEN1 is overexpressed in testis, lung and brain tumors.

Nikolova, T., Christmann, M., & Kaina, B. (2009) · PubMed · Cited by 101 · see citing works

Ethyl methanesulfonate toxicity in Viracept—A comprehensive human risk assessment based on threshold data for genotoxicity

Müller, L., Gocke, E., Lavé, T., & Pfister, T. (2009) · Toxicology Letters · doi:10.1016/j.toxlet.2009.04.003 · Cited by 95 · see citing works

Prognostic impact of O6‐methylguanine‐DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation

Métellus, P., Coulibaly, B., Nanni, I., Fina, F., Eudes, N., Giorgi, R., Barrie, M., Chinot, O. L., Fuentes, S., Dufour, H., et al. (2009) · Cancer · doi:10.1002/cncr.24546 · Cited by 92 · see citing works

Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma

Rabé, M., Dumont, S., Álvarez-Arenas, A., Janati, H., Belmonte-Beitia, J., Calvo, G. F., Thibault-Carpentier, C., Séry, Q., Chauvin, C., Joalland, N., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-019-2200-2 · Cited by 90 · see citing works

Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting

Wang, L., Tang, S., Yu, Y., Lv, Y., Wang, A., Yan, X., Li, N., Sha, C., Sun, K., & Li, Y. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00911 · Cited by 89 · see citing works

Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres

Sciuscio, D., Diserens, A., Dommelen, K. V., Martinet, D., Jones, G., Janzer, R.-C., Pollo, C., Hamou, M., Kaina, B., Stupp, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1931 · Cited by 84 · see citing works

Tunneling Nanotubes Mediate Adaptation of Glioblastoma Cells to Temozolomide and Ionizing Radiation Treatment

Valdebenito, S., Audia, A., Bhat, K., Okafo, G., & Eugenin, E. (2020) · iScience · doi:10.1016/j.isci.2020.101450 · Cited by 58 · see citing works

Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma

del Alcazar, C. R. G., Todorova, P. K., Habib, A. A., Mukherjee, B., & Burma, S. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0125 · Cited by 71 · see citing works

MGMT Promoter Methylation as a Prognostic Factor in Primary Glioblastoma: A Single-Institution Observational Study

Szylberg, M., Sokal, P., Śledzińska, P., Bebyn, M. G., Krajewski, S., Szylberg, Ł., Szylberg, A., Szylberg, T., Krystkiewicz, K., Birski, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10082030 · Cited by 78 · see citing works

Survival kinase genes present prognostic significance in glioblastoma

Varghese, R. T., Liang, Y., Guan, T., Franck, C. T., Kelly, D. F., & Sheng, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.7917 · Cited by 70 · see citing works

Drug resistance in glioblastoma: are persisters the key to therapy?

Oliver, L., Lalier-Bretaudeau, L., Salaud, C., Heymann, D., Cartron, P., & Vallette, F. M. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.29 · Cited by 70 · see citing works

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

Switzeny, O. J., Christmann, M., Renovanz, M., Giese, A., Sommer, C., & Kaina, B. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0204-7 · Cited by 67 · see citing works

MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives

Shaw, R., Basu, M., Karmakar, S., & Ghosh, M. K. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119673 · Cited by 62 · see citing works

Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers

Filippo, L. D. D., Azambuja, J. H., Dutra, J. A. P., Luiz, M. T., Duarte, J. L., Nicoleti, L. R., Saad, S. T. O., & Chorilli, M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.08.011 · Cited by 59 · see citing works

Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?

He, Y., & Kaina, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071562 · Cited by 59 · see citing works

Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma

Stockhammer, F., Misch, M., Koch, A., Czabanka, M., Plotkin, M., Blechschmidt, C., Tuettenberg, J., & Vajkoczy, P. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0192-y · Cited by 56 · see citing works

Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells

Beltzig, L., Schwarzenbach, C., Leukel, P., Frauenknecht, K. B. M., Sommer, C., Tancredi, A., Hegi, M. E., Christmann, M., & Kaina, B. (2022) · Cancers · doi:10.3390/cancers14092233 · Cited by 57 · see citing works

Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53

Kang, H., Kim, C., Han, J. H., Choe, G. Y., Kim, J. H., Kim, J. H., & Kim, I. A. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0305-7 · Cited by 54 · see citing works

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction

Brell, M., Ibáñez, J., & Tortosa, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-35 · Cited by 50 · see citing works

Repair gene O6‐methylguanine‐DNA methyltransferase is controlled by SP1 and up‐regulated by glucocorticoids, but not by temozolomide and radiation

Aasland, D., Reich, T. R., Tomicic, M. T., Switzeny, O. J., Kaina, B., & Christmann, M. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14262 · Cited by 50 · see citing works

The SIAH1–HIPK2–p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death

He, Y., Roos, W. P., Wu, Q., Hofmann, T. G., & Kaina, B. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1306 · Cited by 50 · see citing works

Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications

Kaina, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237442 · Cited by 46 · see citing works

MGMT promoter hypermethylation in a series of 104 glioblastomas.

Mellai, M., Caldera, V., Annovazzi, L., Chiò, A., Lanotte, M., Cassoni, P., Finocchiaro, G., & Schiffer, D. (2009) · PubMed · Cited by 45 · see citing works

O6-methylguanine-DNA methyltransferase (MGMT): impact on cancer risk in response to tobacco smoke

Christmann, M., & Kaina, B. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.06.004 · Cited by 45 · see citing works

Protein Analysis of Glioblastoma Primary and Posttreatment Pairs Suggests a Mesenchymal Shift at Recurrence

Wood, M. D., Reis, G. F., Reuß, D., & Phillips, J. J. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw068 · Cited by 44 · see citing works

A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas

Chai, R., Liu, Y., Zhang, K., Wu, F., Zhao, Z., Wang, K., Jiang, T., & Wang, Y. (2018) · Modern Pathology · doi:10.1038/s41379-018-0143-2 · Cited by 44 · see citing works

The Versatile Attributes of MGMT: Its Repair Mechanism, Crosstalk with Other DNA Repair Pathways, and Its Role in Cancer

Fang, Q. (2024) · Cancers · doi:10.3390/cancers16020331 · Cited by 43 · see citing works

MGMT gene promoter methylation in pediatric glioblastomas

Srivastava, A., Jain, A., Jha, P., Suri, V. S., Sharma, M. C., Mallick, S., Puri, T., Gupta, D. K., Gupta, A., & Sarkar, C. (2010) · Child s Nervous System · doi:10.1007/s00381-010-1214-y · Cited by 41 · see citing works

An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence

Riviere-Cazaux, C., Carlstrom, L. P., Neth, B. J., Olson, I., Rajani, K. R., Rahman, M., Ikram, S., Mansour, M. A., Mukherjee, B., Warrington, A. E., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00476-8 · Cited by 34 · see citing works

Constitutional Mosaic Epimutations – a hidden cause of cancer?

Lønning, P. E., Eikesdal, H. P., Løes, I. M., & Knappskog, S. (2019) · Cell Stress · doi:10.15698/cst2019.04.183 · Cited by 33 · see citing works

Downregulation ofGLS2in glioblastoma cells is related to DNA hypermethylation but not to the p53 status

Szeliga, M., Bogacińska-Karaś, M., Kuzmicz‐Kowalska, K., Rola, R., & Albrecht, J. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22372 · Cited by 35 · see citing works

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models

Cen, L., Carlson, B. L., Pokorny, J. L., Mladek, A. C., Grogan, P. T., Schroeder, M. A., Decker, P. A., Anderson, S. K., Giannini, C., Wu, W., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not010 · Cited by 33 · see citing works

Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53–PUMA Apoptosis Pathway

Tsai, H., Wei, K., Chen, P., Huang, C.-Y., Chen, K., Lin, Y.-J., Cheng, H.-W., Chen, Y.-R., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722754 · Cited by 33 · see citing works

MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas

Micko, A. S. G., Wöehrer, A., Höftberger, R., Vila, G., Marosi, C., Knosp, E., & Wolfsberger, S. (2017) · Pituitary · doi:10.1007/s11102-017-0829-3 · Cited by 31 · see citing works

Association BetweenMGMTPromoter Hypermethylation and p53 Mutation in Glioblastoma

Shamsara, J., Sharif, S., Afsharnezhad, S., Lotfi, M., Raziee, H., Ghaffarzadegan, K., Moradi, A., Rahighi, S., & Behravan, J. (2009) · Cancer Investigation · doi:10.1080/07357900902783211 · Cited by 29 · see citing works

Transfection of a human glioblastoma cell line with liver‐type glutaminase ( LGA ) down‐regulates the expression of DNA ‐repair gene MGMT and sensitizes the cells to alkylating agents

Szeliga, M., Zgrzywa, A., Obara‐Michlewska, M., & Albrecht, J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07917.x · Cited by 28 · see citing works

Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses

Stratenwerth, B., Geisen, S. M., He, Y., Beltzig, L., Sturla, S. J., & Kaina, B. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0228 · Cited by 27 · see citing works

Current and promising treatment strategies in glioma

Śledzińska, P., Bebyn, M. G., Furtak, J., Koper, A., & Koper, K. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0060 · Cited by 27 · see citing works

Certain Imidazotetrazines Escape O6-Methylguanine-DNA Methyltransferase and Mismatch Repair

Zhang, J., Stevens, M. F. G., Hummersone, M., Madhusudan, S., Laughton, C. A., & Bradshaw, T. D. (2011) · Oncology · doi:10.1159/000327837 · Cited by 27 · see citing works

Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors

Tomaszowski, K.-H., Schirrmacher, R., & Kaina, B. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00341 · Cited by 25 · see citing works

Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action

Punganuru, S. R., Arutla, V., Zhao, W., Rajaei, M., Deokar, H. S., Zhang, R., Buolamwini, J. K., Srivenugopal, K. S., & Wang, W. (2020) · Cells · doi:10.3390/cells9071592 · Cited by 22 · see citing works

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells

Ohba, S., Yamashiro, K., & Hirose, Y. (2021) · Cancers · doi:10.3390/cancers13112570 · Cited by 23 · see citing works

O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma

Bobola, M. S., Alnoor, M. S., Chen, J. Y.-S., Kolstoe, D. D., Silbergeld, D. L., Rostomily, R., Blank, A., Chamberlain, M. C., & Silber, J. R. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.11.003 · Cited by 23 · see citing works

65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update

Syro, L. V., Rotondo, F., Ortiz, L. D., & Kovács, K. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0015 · Cited by 23 · see citing works

Progress in high-throughput assays of MGMT and APE1 activities in cell extracts

Georgiadis, P., Polychronaki, N., & Kyrtopoulos, S. Α. (2012) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2012.05.002 · Cited by 22 · see citing works

LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways

Cheng, M., Wang, Q., Chen, L., Zhao, D., Tang, J. X., Xu, J., & He, Z. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.02.016 · Cited by 22 · see citing works

Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook

Gedeon, P. C., Champion, C. D., Rhodin, K. E., Woroniecka, K. I., Kemeny, H. R., Bramall, A. N., Bernstock, J. D., Choi, B. D., & Sampson, J. H. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1817737 · Cited by 21 · see citing works

Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma

Voelter, V., Diserens, A., Moulin, A., Nagel, G., Yan, P., Migliavacca, E., Rimoldi, D., Hamou, M., Kaina, B., Leyvraz, S., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23632 · Cited by 21 · see citing works

The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage

Baran, K., Yang, M., Dillon, C. P., Samson, L. D., & Green, D. R. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.116 · Cited by 20 · see citing works

High expression of LncRNA HOTAIR is a risk factor for temozolomide resistance in glioblastoma via activation of the miR-214/β-catenin/MGMT pathway

Lan, T., Quan, W., Yu, D., Chen, X., Wang, X., & Li, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-77348-z · Cited by 18 · see citing works

Functional Blockade of Small GTPase RAN Inhibits Glioblastoma Cell Viability

Sheng, K. L., Pridham, K. J., Sheng, Z., Lamouille, S., & Varghese, R. T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00662 · Cited by 18 · see citing works

In search of effective therapies to overcome resistance to Temozolomide in brain tumours

Bouzinab, K., Summers, H. S., Zhang, J., Stevens, M. F. G., Moody, C. J., Turyanska, L., Thomas, N. R., Gershkovich, P., Ashford, M. B., Vitterso, E., et al. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.64 · Cited by 17 · see citing works

Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells

Beltzig, L., Stratenwerth, B., & Kaina, B. (2021) · Cancers · doi:10.3390/cancers13246287 · Cited by 16 · see citing works

BMX, a specific HDAC8 inhibitor, with TMZ for advanced CRC therapy: a novel synergic effect to elicit p53-, β-catenin- and MGMT-dependent apoptotic cell death

Ko, H.-J., Chiou, S.-J., Tsai, C.-Y., Loh, J., Lin, X., Tran, T.-H., Hou, C.-C., Cheng, T., Lai, J.-M., Chang, P. M., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-01007-x · Cited by 16 · see citing works

MGMT Methylation and Differential Survival Impact by Sex in Glioblastoma

Barnett, A. E., Ozair, A., Bamashmos, A. S., Li, H., Bosler, D. S., Yeaney, G. A., Ali, A., Peereboom, D. M., Lathia, J. D., & Ahluwalia, M. S. (2024) · Cancers · doi:10.3390/cancers16071374 · Cited by 15 · see citing works

The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma

Villani, V., Casini, B., Pace, A., Prosperini, L., Carapella, C. M., Vidiri, A., Fabi, A., & Carosi, M. (2015) · Disease Markers · doi:10.1155/2015/604719 · Cited by 15 · see citing works

Methylation of DNA repair genes and the efficacy of DNA targeted anticancer treatment

Julsing, J. R., & Peters, G. J. (2014) · Oncology Discovery · doi:10.7243/2052-6199-2-3 · Cited by 14 · see citing works

Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?

Franzese, O., Torino, F., Giannetti, E., Cioccoloni, G., Aquino, A., Faraoni, I., Fuggetta, M. P., Vecchis, L. D., Giuliani, A., Kaina, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910672 · Cited by 12 · see citing works

End Processing Factor APLF Promotes NHEJ Efficiency and Contributes to TMZ- and Ionizing Radiation-Resistance in Glioblastoma Cells

Dong, W., Li, L., Teng, X., Yang, X., Si, S., & Chai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s254292 · Cited by 13 · see citing works

Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study

Yu, Y., Wang, L., Han, J., Wang, A., Chu, L., Xi, X., Kan, R., Sha, C., & Sun, K. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.06.025 · Cited by 13 · see citing works

Targeting Key Signaling Pathways in Glioblastoma Stem Cells for the Development of Efficient Chemo- and Immunotherapy

Helweg, L. P., Storm, J., Witte, K. E., Schulten, W., Wrachtrup, L., Janotte, T., Kitke, A., Greiner, J. F. W., Knabbe, C., Kaltschmidt, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112919 · Cited by 12 · see citing works

Immunohistochemical Assessment of MGMT Expression and p53 Mutation in Glioblastoma Multiforme

Lotfi, M., Afsharnezhad, S., Raziee, H., Ghaffarzadegan, K., Sharif, S., Shamsara, J., Lary, S., & Behravan, J. (2011) · Tumori Journal · doi:10.1177/030089161109700118 · Cited by 12 · see citing works

The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma

Suzuki, T., Nakada, M., Yoshida, Y., Nambu, E., Furuyama, N., Kita, D., Hayashi, Y., Hayashi, Y., & Hamada, J. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq224 · Cited by 12 · see citing works

Therapy and progression – induced O6-methylguanine-DNA methyltransferase and mismatch repair alterations in recurrent glioblastoma multiforme

Sarkar, C., Agarwal, S., Suri, V. S., & Sharma, M. (2015) · Indian Journal of Cancer · doi:10.4103/0019-509x.178403 · Cited by 11 · see citing works

Repair of O6-carboxymethylguanine adducts by O6-methylguanine-DNA methyltransferase in human colon epithelial cells

Kostka, T., Empl, M. T., Seiwert, N., Geisen, S. M., Hoffmann, P., Adam, J., Seeger, B., Shay, J. W., Christmann, M., Sturla, S. J., et al. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab049 · Cited by 10 · see citing works

Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy

Arnesen, V. S., Navarro, A. G., & Chekenya, M. (2021) · Cancers · doi:10.3390/cancers13194986 · Cited by 8 · see citing works

hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity

Zhang, J., Yin, D., & LI, H. (2014) · Oncology Reports · doi:10.3892/or.2014.3430 · Cited by 7 · see citing works

Modulating glioblastoma chemotherapy response: Evaluating long non-coding RNA effects on DNA damage response, glioma stem cell function, and hypoxic processes

Yuan, E., Liu, K., Lee, J., Tsung, K., Chow, F. E., & Attenello, F. J. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac119 · Cited by 7 · see citing works

Intérêt de la MGMT dans les gliomes

Quillien, V., Vauléon, É., Saïkali, S., Lesimple, T., Hamlat, A., Etcheverry, A., & Mosser, J. (2011) · Bulletin du Cancer · doi:10.1684/bdc.2011.1332 · Cited by 7 · see citing works

Case comparison and literature review of glioblastoma: A tale of two tumors

Ross, D., Mendez, G. A., Ozpinar, A., Raskin, J. S., & Gultekin, S. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.138034 · Cited by 7 · see citing works

MGMT activity in mucosal epithelium and squamous cell carcinoma of the head and neck.

Jacob, R., Shafiei, N., Nagel, G., Welkoborsky, H. J., Mann, W. J., & Kaina, B. (2010) · PubMed · Cited by 7 · see citing works

Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss

Li, X., Wei, J., Liu, Y., Li, P., Fan, L., Wang, Y., Li, M., Zhao, D., Yu, Z., Ye, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13272-9 · Cited by 7 · see citing works

BAG1, MGMT, FOXO1 , and DNAJA1 as potential drug targets for radiosensitizing cancer cell lines

Manunu, B., Serafin, A. M., & Akudugu, J. (2022) · International Journal of Radiation Biology · doi:10.1080/09553002.2022.2074164 · Cited by 6 · see citing works

Revisiting an old therapy for new, promising combinations: Biology and perspectives of lomustine in glioma treatment

Bellamy, C., Hajal, C., Ligon, K. L., & Touat, M. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf192 · Cited by 5 · see citing works

Normalized Apparent Diffusion Coefficient in the Prognostication of Patients with Glioblastoma Multiforme

Shankar, J., Bata, A., Ritchie, K., Hebb, A. L. O., & Walling, S. A. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2015.356 · Cited by 5 · see citing works

Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies

Kurdi, M. E., Butt, N. S., Baeesa, S. S., Alghamdi, B. S. A., Maghrabi, Y., Bardeesi, A. M., Saeedi, R., Dallol, A., Mohamed, F., Bari, M. O., et al. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03723-9 · Cited by 5 · see citing works

Stereotactic image‑based histological analysis reveals a correlation between 11C‑methionine uptake and MGMT promoter methylation in non‑enhancing gliomas

Okita, Y., Shofuda, T., Kanematsu, D., Yoshioka, E., Kodama, Y., Mano, M., Kinoshita, M., Nonaka, M., Nakajima, S., Fujinaka, T., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8866 · Cited by 5 · see citing works

Constitutional Epimutations: From Rare Events Toward Major Cancer Risk Factors?

Lønning, P. E., Nikolaienko, O., & Knappskog, S. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00746 · Cited by 8 · see citing works

A Consideration ofMGMTGene Promotor Methylation Analysis for Glioblastoma Using Methylation-Specific Polymerase Chain Reaction and Pyrosequencing

Lee, S. H., Hwang, T. S., Koh, Y.-C., Kim, W. Y., Han, H. S., Kim, W. S., Ko, Y. S., & Lim, S. D. (2011) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2011.45.1.21 · Cited by 4 · see citing works

Motivating the additional use of external validity: examining transportability in a model of glioblastoma multiforme.

Singleton, K., Speier, W. F., Bui, A. A. T., & Hsu, W. W. Y. (2014) · PubMed Central · Cited by 4 · see citing works

MGMT—a critical DNA repair gene target for chemotherapy resistance

Christmann, M., & Kaina, B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00002-4 · Cited by 4 · see citing works

EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma

Nayab, A., Mughal, N., Angez, M., Xing, S., Burma, A. M., Balla, H., Kizilbash, S. H., Yang, X., Maqbool, M. A., Arain, F. M., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx8398 · Cited by 3 · see citing works

Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics

Lasri, A., Jurić, V., Verreault, M., Bielle, F., Idbaïh, A., Kel, A. E., Murphy, B. M., & Sturrock, M. (2020) · Royal Society Open Science · doi:10.1098/rsos.191243 · Cited by 3 · see citing works

DNA repair, damage signaling and carcinogenesis

Lavelle, C., Salles, B., & Wiesmüller, L. (2008) · DNA repair · doi:10.1016/j.dnarep.2007.12.007 · Cited by 3 · see citing works

High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties

Zhang, J. Y., Rajendran, B. K., Desai, S., Gibson, J. A., DiPalermo, J., LoRusso, P. M., Kong, Y., Zhao, H., Cecchini, M., & Schalper, K. A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011653 · Cited by 1 · see citing works

O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma

Bobola, M. S., Alnoor, M. S., Chen, J. Y.-S., Kolstoe, D. D., Silbergeld, D. L., Rostomily, R., Blank, A., Chamberlain, M. C., & Silber, J. R. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.11.003 · Cited by 23 · see citing works

O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems

Silber, J. R., Bobola, M. S., Blank, A., & Chamberlain, M. C. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.004 · Cited by 115 · see citing works

Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors

Park, T., Riethdorf, S., Riethdorf, L., L�ning, T., & J�nicke, F. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990820)84:4 · Cited by 56 · see citing works

MGMT Promoter Methylation is Predictive of Radiotherapy Outcomes for Newly-Diagnosed Glioblastomas and is not Prognostic in the Absence of Radiotherapy

Lamba, N., & Iorgulescu, B. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.07.2004 · Cited by 2 · see citing works

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy.

Silber, J. R., Blank, A., Bobola, M. S., Ghatan, S., Kolstoe, D. D., & Berger, M. S. (1999) · PubMed · Cited by 135 · see citing works